Recruiting OBSERVATIONAL NCT07321808

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients (AID4FRAIL_RZV)

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine (RZV) in Frail Patients: Multicentric Prospective Study

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Conditions Immunocompromised Patients

Updated 2 times since 2026 Last updated: Mar 3, 2026 Started: May 16, 2023 Primary completion: May 31, 2027 Completion: May 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07321808, this observational or N/A phase trial focuses on Immunocompromised Patients and remains actively recruiting participants. Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia, it has been updated 2 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Mar 2026 — Present [monthly]

Recruiting
Feb 2026 — Mar 2026 [monthly]

Recruiting

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione IRCCS Policlinico San Matteo di Pavia

Data source: Fondazione IRCCS Policlinico San Matteo di Pavia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pavia, Italy